Welcome to Imagion Biosystems Limited's Extraordinary General Meeting (EGM) held in Melbourne and online. In this hybrid forum, Chairman Bob Proulx presides over the meeting. Directors, including Mark Van Asten, Jovanka Naumoska, and David Ludvigson, are introduced, with CEO Dr. Isaac Bright and CFO Geoff Hollis present virtually and in person.

The agenda includes six resolutions, with a special focus on Imagion's groundbreaking MagSense platform for molecular MRI. Dr. Isaac Bright presents recent developments, highlighting MagSense's potential in detecting HER2+ breast cancer and its applications in various cancer types. The company's strategy involves forming partnerships and collaborations to advance MagSense products globally.

Resolutions cover key topics such as the election of Dr. Isaac Bright as a director, the consolidation of shares, approval of future convertible notes and options to Mercer Street Global Opportunity Fund, issuance of options to directors, issuance of options to Dr. Isaac Bright, and the adoption of a new constitution.

Bob Proulx explains the rationale behind the resolutions, emphasizing their alignment with fiscal prudence while positioning the company for future success. The meeting also addresses shareholder queries, ensuring transparency and clarity.

The voting process is conducted online, allowing shareholders to participate in decision-making.

The presentation concludes with a vote on each resolution, ensuring active shareholder engagement. The company expresses gratitude for shareholder support, and the meeting is officially closed.

Stay tuned for further updates on Imagion Biosystems Limited's groundbreaking advancements in molecular MRI technology.